Mealey's (September 5, 2018, 9:31 AM EDT) -- SAN FRANCISCO — In partially reversing and remanding a federal district court’s dismissal of a securities class action lawsuit against a pharmaceutical company and certain of its senior executives, a Ninth Circuit U.S. Court of Appeals panel on Aug. 13 ruled that the district court abused its discretion in judicially noticing several documents and facts but properly took judicial notice of the date of the company’s international patent application for its obesity treatment drug that was subject of the litigation (Karim Khoja v. Orexigen Therapeutics Inc., et al., No. 16-56069, 9th Cir., 2018 U.S. App. LEXIS 22371)....